RxDoctor Payments Data

Hamed Shabaneh Al-Tamimi, MD

Gastroenterology · Lubbock, TXNPI 1396757233

Payments from drug & device makers

$26,220in general payments, 2019–2025

Across 151 payments — averaging $173.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$24K
  • Takeda Pharmaceuticals U.S.A., Inc.$617
  • Pfizer$177
  • Boston Scientific$163
  • Ardelyx, Inc.$137
  • Gilead$133
  • plus $1K from 21 others

What the payments were for

  • Consulting fees$350%
  • Speaking & faculty fees$21,20381%
  • Travel & lodging$9444%
  • Food & beverage$4,03815%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,220 in reported general payments places this provider in the 80th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$121,480
Medicare patients
218
Services billed
1,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide144$92,037
CreonLipase/Protease/Amylase25$84,600
XifaxanRifaximin15$57,046
Mesalamine27$8,821
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates104$6,556
Pantoprazole Sodium553$5,349
Sucralfate80$4,897
Dicyclomine Hcl98$2,814
Famotidine140$1,326
Peg3350-Sod Sul-Nacl-Kcl-Asb-CPeg3350/Sod Sul/Nacl/Kcl/Asb/C16$1,139
Budesonide DrBudesonide13$974
Azathioprine23$895
Omeprazole87$883
Metoclopramide Hcl96$562
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl26$450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$23,822$176,636169 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$120$57,04615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →